Ask AI

Advancing the Frontier in Ovarian Cancer: Interpreting Emerging Clinical Evidence for CDH6-Targeted ADCs

Optimize care for patients with ovarian cancer by increasing your knowledge of CDH6-targeted antibody–drug conjugates through an expert-written ClinicalThought commentary, a podcast, and certified video modules with accompanying downloadable slides.

Share

Program Content

Activities

Targeting CDH6 in PROC
Targeting CDH6 in Platinum-Resistant Ovarian Cancer: Emerging ADCs, Biomarkers, and Sequencing
Podcast
Congratulations: You achieved a completion on 04/09/2022

Released: September 08, 2026

Activities

Biology of CDH6 in Ovarian Cancer
The Scientific Rationale for Targeting CDH6 in Ovarian Cancer and the Biology of CDH6
Video
Congratulations: You achieved a completion on 04/09/2022

Released: October 16, 2026

Expires: April 15, 2027

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

Supporters

This activity is supported by educational grants from Daiichi Sankyo, Inc and Merck Sharp & Dohme LLC.

Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC